The aim of the trial is to investigate relative bioavailability of BI 3034701 treatment T vs. BI 3034701 treatment R.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
BI3034701 formulation B (reference treatment)
BI3034701 formulation C1 (test treatment)
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to 19 days.
Maximum measured concentration of the analyte in plasma (Cmax)
Highest observed plasma concentrations within the time interval.
Time frame: Up to 19 days.
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 19 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.